These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 33178324)

  • 1. Adjuvant Fuzheng Huayu Capsule Reduces the Incidence of Hepatocellular Carcinoma in Patients with Hepatitis B-Caused Cirrhosis.
    Shi K; Liu Y; Wang X; Li Y; Zhang Q; Hu Y; Ran C; Huang Y; Hou J; Wang X
    Evid Based Complement Alternat Med; 2020; 2020():8826091. PubMed ID: 33178324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beneficial Effects of Traditional Chinese Medicine Fuzheng Huayu on the Occurrence of Hepatocellular Carcinoma in Patients with Compensated Chronic Hepatitis B Cirrhosis Receiving Entecavir: A Multicenter Retrospective Cohort Study.
    Fan H; Lei S; Zhao Z; Huang Y; Wang H; Liu X; Li X; Xu M; Zhang W; Sun K; Xing H; Mei Y; Huang J; Zhu C; Zhang K; Zong Y; Shen X; Xie Q; Liu C
    J Clin Transl Hepatol; 2024 May; 12(5):505-515. PubMed ID: 38779515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Fuzheng Huayu capsules reducing development of hepatocellular carcinoma in cirrhotic patients with chronic hepatitis B based on the ratio of neutrophils/lymphocytes].
    Shi K; Hou J; Zhang Y; Bi YF; Wang XB
    Zhonghua Gan Zang Bing Za Zhi; 2023 Sep; 31(9):969-973. PubMed ID: 37872093
    [No Abstract]   [Full Text] [Related]  

  • 4. Transcriptional Profiling and miRNA-Target Network Analysis Identify Potential Biomarkers for Efficacy Evaluation of Fuzheng-Huayu Formula-Treated Hepatitis B Caused Liver Cirrhosis.
    Chen Q; Wu F; Wang M; Dong S; Liu Y; Lu Y; Song Y; Zhou Q; Liu P; Luo Y; Su S
    Int J Mol Sci; 2016 Jun; 17(6):. PubMed ID: 27271613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic efficacy of fuzheng-huayu tablet based traditional chinese medicine syndrome differentiation on hepatitis-B-caused cirrhosis: a multicenter double-blind randomized controlled trail.
    Song YN; Sun JJ; Lu YY; Xu LM; Gao YQ; Zhang W; Wang XS; Xue DY; Zheng QS; Su SB
    Evid Based Complement Alternat Med; 2013; 2013():709305. PubMed ID: 23533516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Curative Effects of ZHENG-Based Fuzheng-Huayu Tablet on Hepatitis B Caused Cirrhosis Related to CYP1A2 Genetic Polymorphism.
    Li QY; Guo ZZ; Deng X; Xu LM; Gao YQ; Zhang W; Wang XS; Xue DY; Lu YY; Liu P; Su SB
    Evid Based Complement Alternat Med; 2013; 2013():302131. PubMed ID: 24282434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fuzheng Huayu capsule as an adjuvant treatment for HBV-related cirrhosis: A systematic review and meta-analysis.
    Wang T; Zhou X; Liu H; Wang J; Zhang P; Zhu Y; Li K; Wei S; Li H; Wang L; Wang R; Zhao Y
    Phytother Res; 2018 May; 32(5):757-768. PubMed ID: 29235181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of Fuzheng Huayu capsule on inhibiting the fibrosis-associated hepatocellular carcinogenesis.
    Zhang WQ; Sun JX; Lan ST; Sun XM; Guo YJ; Wen BC; Chen J; Liu G
    J Asian Nat Prod Res; 2024 Oct; 26(10):1219-1238. PubMed ID: 38780602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dynamical Regulation Analysis Identifies Molecular Mechanisms of Fuzheng-Huayu Formula against Hepatitis B-Caused Liver Cirrhosis.
    Chen QL; Lu YY; Peng JH; Dong S; Wei B; Song YN; Zhou QM; Zhang H; Liu P; Su SB
    Evid Based Complement Alternat Med; 2015; 2015():238495. PubMed ID: 26221171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Nucleos(t)ide Analogs on Patients with Intermediate and Advanced Hepatitis B Virus-Related Hepatocellular Carcinoma.
    Jian ZW; Wu XW; Chen ZX; Wang JC; Peng JY; Lao XM
    Dig Dis Sci; 2019 Aug; 64(8):2187-2198. PubMed ID: 30815819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Interferon-α-based therapy and nucleos(t)ide analogs in preventing adverse outcomes in patients with chronic hepatitis B.
    Mao QG; Liang HQ; Yin YL; Tang JM; Yang JE; Wu CC; Chen Y; Zhang MY; Liu YY; Zheng XT; Zhuang LY; Chen SD
    Clin Res Hepatol Gastroenterol; 2022 Jan; 46(1):101758. PubMed ID: 34303003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon-based treatment is superior to nucleos(t)ide analog in reducing HBV-related hepatocellular carcinoma for chronic hepatitis B patients at high risk.
    Ren P; Cao Z; Mo R; Liu Y; Chen L; Li Z; Zhou T; Lu J; Liu Y; Guo Q; Chen R; Zhou H; Xiang X; Cai W; Wang H; Bao S; Xu Y; Gui H; Xie Q
    Expert Opin Biol Ther; 2018 Oct; 18(10):1085-1094. PubMed ID: 30182763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nucleos(t)ide analogues associated with a reduced risk of hepatocellular carcinoma in hepatitis B patients: a population-based cohort study.
    Wang JP; Kao FY; Wu CY; Hung YP; Chao Y; Chou YJ; Li CP
    Cancer; 2015 May; 121(9):1446-55. PubMed ID: 25537961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fuzheng Huayu Capsule Attenuates Hepatic Fibrosis by Inhibiting Activation of Hepatic Stellate Cells.
    Wu M; Zhou Y; Qin SL; Lin LJ; Ping J; Tao Z; Zhang J; Xu LM; Wu J
    Evid Based Complement Alternat Med; 2020; 2020():3468791. PubMed ID: 32454856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Entecavir and Low Genetic Barrier Antiviral Agents for Hepatocellular Carcinoma in Hepatitis B Viral Cirrhosis: Propensity Score Matching.
    Li T; Qu Y; Wang Y; Lin C; Yang B; Wang L
    J Coll Physicians Surg Pak; 2019 Apr; 29(4):317-323. PubMed ID: 30925952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutrophil-lymphocyte ratio and the risk of hepatocellular carcinoma in patients with hepatitis B-caused cirrhosis.
    Shi K; Li P; Xue D; Liu Y; Zhang Q; Ping R; Wang X
    Eur J Gastroenterol Hepatol; 2021 Dec; 33(1S Suppl 1):e686-e692. PubMed ID: 34074986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. External validation of the Toronto hepatocellular carcinoma risk index in a Swedish population.
    Åström H; Ndegwa N; Hagström H
    JHEP Rep; 2021 Oct; 3(5):100343. PubMed ID: 34611618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progress in clinical and basic research of fuzheng Huayu formula for the treatment of liver fibrosis.
    Zhou X; Fu Y; Chen J; Liu P
    J Ethnopharmacol; 2024 Jun; 327():118018. PubMed ID: 38453100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world study on clinical outcomes of nucleos(t)ide analogues antiviral therapy in patients with chronic hepatitis B.
    Sun Y; Zhang Y; Xu Y; Shu M; Bonroy K; Qiu H; Cai W
    Epidemiol Infect; 2019 Jan; 147():e193. PubMed ID: 31364558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized clinical trial: Nucleos(t)ide analogues improved survival of CHB-related HCC patients via reducing severity and progression of malignancy.
    Wang Y; Xiang X; Chen L; Cao Z; Bao R; Zhou H; Tang W; Lu J; Lin L; Xie Q; Bao S; Wang H
    Oncotarget; 2016 Sep; 7(36):58553-58562. PubMed ID: 27329718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.